Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »
2/115 von 416    DIMDI: MEDLINE (ME60) © NLM
ND: ME15860188
PMID: 15860188
LR: 20061115
CED: 20050429
DCO: 20050623
Autoren: Mulero Mendoza J
Titel: Tratamiento farmacológico de la artrosis. Expectativas y realidades.
Pharmacological treatment of osteoarthritis. Expectations and reality
Quelle: Revista clínica española; VOL: 205 (4); p. 168-71 /200504/
PM: Print
SU: IM
Sprache: Spanish
CY: Spain
JID: 8608576
ISSN: 0014-2565
CO: RCESA5
Institution: Servicio de Reumatología, Hospital Puerta de Hierro, Madrid.
DT: English Abstract; Journal Article
Schlagwörter
CT: ANTHRAQUINONES/*therapeutic use; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/*therapeutic use; CHONDROITIN SULFATES/*therapeutic use; GLUCOSAMINE/*therapeutic use; HUMANS; OSTEOARTHRITIS/*drug therapy
CTG: ANTHRACHINONE/*therapeutische Anwendung; ANTIPHLOGISTIKA, NICHTSTEROIDALE/*therapeutische Anwendung; CHONDROITINSULFATE/*therapeutische Anwendung; GLUCOSAMIN/*therapeutische Anwendung; MENSCH; OSTEOARTHROSE/*Arzneimitteltherapie
TE: Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; diacetylrhein/13739-02-1; Glucosamine/3416-24-8; Chondroitin Sulfates/9007-28-7
CR: 13739-02-1; 3416-24-8; 9007-28-7
AB: In order to assess agent with modulating properties of the course of the arthrosic condition, the so-called SYSADOA (Symptomatic Slow Acting Drugs for Osteoarthritis) and "structure modifiers" have been defined. Glucosamine sulfate, chrondroitin sulfate and diacerein have been considered among these agents. Based on the published data and according to the evidence available, the SYSADOA have symptomatic effects and can modify the structure. However, although there is scientific evidence for the use of these drugs in arthrosis treatment, the limited intensity of their action over the placebo makes it necessary to evaluate the clinical relevance of their application before recommending their generalized use.
» Volltext »

» Fenster schließen »